PDF(Pubmed)
Abstract：
SMARCA4-deficient non-small cell carcinoma is an aggressive neoplasm with poor outcome. Several studies have highlighted its immunochemistry, pathophysiology, and underlying mechanisms, but studies of its definite treatment are few. Here, we report on a 69-year-old male with heterogenous pathological presentations of SMARCA4-deficient non-small cell carcinoma. He initially presented with neck lymphadenopathies. Immunohistochemistry staining and genomic profiling confirmed the diagnosis of SMARCA4-deficient non-small cell carcinoma. The patient responded well to immune checkpoint inhibitors with nivolumab. However, new lesions with various pathological presentations and various responses to nivolumab appeared during the treatment course. The patient survived more than 3 years from the initial diagnosis. This case shows the efficacy of nivolumab to treat SMARCA4-deficient non-small cell lung carcinoma.
摘要：
SMARCA4缺陷型非小细胞癌是一种预后不良的侵袭性肿瘤。几项研究强调了它的免疫化学，病理生理学,和潜在的机制，但是对其确切治疗的研究很少。这里,我们报道了一名69岁男性，其病理表现为SMARCA4缺陷型非小细胞癌的异质性。他最初表现为颈部淋巴结肿大。免疫组织化学染色和基因组谱分析证实了SMARCA4缺陷型非小细胞癌的诊断。患者对nivolumab的免疫检查点抑制剂反应良好。然而,在治疗过程中出现了具有各种病理表现和对nivolumab的各种反应的新病变.患者从最初诊断起存活超过3年。该病例显示了纳武单抗治疗SMARCA4缺陷型非小细胞肺癌的疗效。
